Cargando…

Discovery of Novel Cyclic Ethers with Synergistic Antiplasmodial Activity in Combination with Valinomycin

With drug resistance threatening our first line antimalarial treatments, novel chemotherapeutics need to be developed. Ionophores have garnered interest as novel antimalarials due to their theorized ability to target unique systems found in the Plasmodium-infected erythrocyte. In this study, during...

Descripción completa

Detalles Bibliográficos
Autores principales: Watson, Daniel J., Meyers, Paul R., Acquah, Kojo Sekyi, Dziwornu, Godwin A., Barnett, Christopher Bevan, Wiesner, Lubbe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708982/
https://www.ncbi.nlm.nih.gov/pubmed/34946577
http://dx.doi.org/10.3390/molecules26247494
_version_ 1784622820849876992
author Watson, Daniel J.
Meyers, Paul R.
Acquah, Kojo Sekyi
Dziwornu, Godwin A.
Barnett, Christopher Bevan
Wiesner, Lubbe
author_facet Watson, Daniel J.
Meyers, Paul R.
Acquah, Kojo Sekyi
Dziwornu, Godwin A.
Barnett, Christopher Bevan
Wiesner, Lubbe
author_sort Watson, Daniel J.
collection PubMed
description With drug resistance threatening our first line antimalarial treatments, novel chemotherapeutics need to be developed. Ionophores have garnered interest as novel antimalarials due to their theorized ability to target unique systems found in the Plasmodium-infected erythrocyte. In this study, during the bioassay-guided fractionation of the crude extract of Streptomyces strain PR3, a group of cyclodepsipeptides, including valinomycin, and a novel class of cyclic ethers were identified and elucidated. Further study revealed that the ethers were cyclic polypropylene glycol (cPPG) oligomers that had leached into the bacterial culture from an extraction resin. Molecular dynamics analysis suggests that these ethers are able to bind cations such as K(+), NH(4)(+) and Na(+). Combination studies using the fixed ratio isobologram method revealed that the cPPGs synergistically improved the antiplasmodial activity of valinomycin and reduced its cytotoxicity in vitro. The IC(50) of valinomycin against P. falciparum NF54 improved by 4–5-fold when valinomycin was combined with the cPPGs. Precisely, it was improved from 3.75 ± 0.77 ng/mL to 0.90 ± 0.2 ng/mL and 0.75 ± 0.08 ng/mL when dosed in the fixed ratios of 3:2 and 2:3 of valinomycin to cPPGs, respectively. Each fixed ratio combination displayed cytotoxicity (IC(50)) against the Chinese Hamster Ovary cell line of 57–65 µg/mL, which was lower than that of valinomycin (12.4 µg/mL). These results indicate that combinations with these novel ethers may be useful in repurposing valinomycin into a suitable and effective antimalarial.
format Online
Article
Text
id pubmed-8708982
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87089822021-12-25 Discovery of Novel Cyclic Ethers with Synergistic Antiplasmodial Activity in Combination with Valinomycin Watson, Daniel J. Meyers, Paul R. Acquah, Kojo Sekyi Dziwornu, Godwin A. Barnett, Christopher Bevan Wiesner, Lubbe Molecules Article With drug resistance threatening our first line antimalarial treatments, novel chemotherapeutics need to be developed. Ionophores have garnered interest as novel antimalarials due to their theorized ability to target unique systems found in the Plasmodium-infected erythrocyte. In this study, during the bioassay-guided fractionation of the crude extract of Streptomyces strain PR3, a group of cyclodepsipeptides, including valinomycin, and a novel class of cyclic ethers were identified and elucidated. Further study revealed that the ethers were cyclic polypropylene glycol (cPPG) oligomers that had leached into the bacterial culture from an extraction resin. Molecular dynamics analysis suggests that these ethers are able to bind cations such as K(+), NH(4)(+) and Na(+). Combination studies using the fixed ratio isobologram method revealed that the cPPGs synergistically improved the antiplasmodial activity of valinomycin and reduced its cytotoxicity in vitro. The IC(50) of valinomycin against P. falciparum NF54 improved by 4–5-fold when valinomycin was combined with the cPPGs. Precisely, it was improved from 3.75 ± 0.77 ng/mL to 0.90 ± 0.2 ng/mL and 0.75 ± 0.08 ng/mL when dosed in the fixed ratios of 3:2 and 2:3 of valinomycin to cPPGs, respectively. Each fixed ratio combination displayed cytotoxicity (IC(50)) against the Chinese Hamster Ovary cell line of 57–65 µg/mL, which was lower than that of valinomycin (12.4 µg/mL). These results indicate that combinations with these novel ethers may be useful in repurposing valinomycin into a suitable and effective antimalarial. MDPI 2021-12-10 /pmc/articles/PMC8708982/ /pubmed/34946577 http://dx.doi.org/10.3390/molecules26247494 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Watson, Daniel J.
Meyers, Paul R.
Acquah, Kojo Sekyi
Dziwornu, Godwin A.
Barnett, Christopher Bevan
Wiesner, Lubbe
Discovery of Novel Cyclic Ethers with Synergistic Antiplasmodial Activity in Combination with Valinomycin
title Discovery of Novel Cyclic Ethers with Synergistic Antiplasmodial Activity in Combination with Valinomycin
title_full Discovery of Novel Cyclic Ethers with Synergistic Antiplasmodial Activity in Combination with Valinomycin
title_fullStr Discovery of Novel Cyclic Ethers with Synergistic Antiplasmodial Activity in Combination with Valinomycin
title_full_unstemmed Discovery of Novel Cyclic Ethers with Synergistic Antiplasmodial Activity in Combination with Valinomycin
title_short Discovery of Novel Cyclic Ethers with Synergistic Antiplasmodial Activity in Combination with Valinomycin
title_sort discovery of novel cyclic ethers with synergistic antiplasmodial activity in combination with valinomycin
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708982/
https://www.ncbi.nlm.nih.gov/pubmed/34946577
http://dx.doi.org/10.3390/molecules26247494
work_keys_str_mv AT watsondanielj discoveryofnovelcyclicetherswithsynergisticantiplasmodialactivityincombinationwithvalinomycin
AT meyerspaulr discoveryofnovelcyclicetherswithsynergisticantiplasmodialactivityincombinationwithvalinomycin
AT acquahkojosekyi discoveryofnovelcyclicetherswithsynergisticantiplasmodialactivityincombinationwithvalinomycin
AT dziwornugodwina discoveryofnovelcyclicetherswithsynergisticantiplasmodialactivityincombinationwithvalinomycin
AT barnettchristopherbevan discoveryofnovelcyclicetherswithsynergisticantiplasmodialactivityincombinationwithvalinomycin
AT wiesnerlubbe discoveryofnovelcyclicetherswithsynergisticantiplasmodialactivityincombinationwithvalinomycin